Overview
| 别名 | Protein phosphatase 1 regulatory subunit 14A; 17 kDa PKC-potentiated inhibitory protein of PP1; Protein kinase C-potentiated inhibitor protein of 17 kDa; CPI-17 |
| 基因名 | PPP1R14A |
| UniProt ID | Q96A00 |
| 反应种属 | Human |
| 应用 | IHC-P,ELISA |
| 宿主 | Mouse |
| 偶联物 | Unconjugated |
| 修饰 | Unmodified |
| 亚型 | IgG2a |
| 克隆号 | 4G1-G4-C7 |
| 克隆性 | Monoclonal Antibody |
| 分子量 | Calculated MW: 16 kDa |
| 纯化方式 | Affinity Purified |
| 产品形式 | Liquid |
| 推荐稀释比 | IHC-1:100-1:200; ELISA-1:200 |
| 存储缓冲液 | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% sodium azide |
| 保存温度 | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| 背景信息 | Protein phosphatase 1 regulatory inhibitor subunit 14A (PPP1R14A), also known as CPI-17, is a protein that plays a crucial role in regulating smooth muscle contraction and has been implicated in various cancers. It acts as a phosphorylation-dependent inhibitor of smooth muscle myosin phosphatase, with over 1000-fold higher inhibitory activity when phosphorylated, creating a molecular switch for regulating the phosphorylation state of PPP1CA substrate and smooth muscle contraction. In cancer, PPP1R14A has been associated with tumorigenesis and progression, particularly in sporadic vestibular glioma, human melanoma, and schwannoma. High expression of PPP1R14A in most cases is linked to poor overall survival, disease-specific survival, and progress-free interval across patients with various malignant tumors, including adrenocortical carcinoma and bladder urothelial carcinoma. |
检测原理